Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

John Ciampaglia: Uranium Facing Tight Supply, Pent-up Demand — Plus AI, Election Impact

13 Canadian Crypto ETFs (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

How Could Trump's US Election Win Affect the Gold Price?

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Leigh Goehring: Gold's "Massive Bull Market" Just Starting; Uranium and Copper Outlook

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Can You Invest in Elon Musk’s Neuralink? (Updated 2024)

Top 4 Largest Lithium Reserves by Country (Updated 2024)

Trending Press Releases

Ashburton Drilling Programme Delivers Further Significant Uranium Intersections

$4.5M Government Grant Secures Construction Start for Collie Micronising Facility

Altech Batteries Limited (ASX: ATC) – Trading Halt

Bitcoin Well Provides Update to the Bitcoin Super Company Vision and Bitcoin Reserve Fund

Silver47 Commences Trading on the TSXV

First Helium Initiates Process to License & Drill the Leduc Anomaly

More Press Releases
Trending Companies

Purpose Bitcoin ETF

BTCC:CA

Soma Gold Corp.

SOMA:CA

Silver47 Exploration

AGA:CC

Black Swan Graphene

SWAN:CC
More Companies
Trending Reports

2024 Lithium Market Outlook

2024 Uranium Outlook

2024 Gold Outlook Report

Silver Price Forecast - What Happened And Where Do We Go From Here?

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Pardes Biosciences Inc.

NASDAQ:PRDS
Press Releases

Pardes Biosciences Inc is a clinical-stage biopharmaceutical company created for solving pandemic-sized problems, starting with COVID-19. It applies reversible-covalent chemistry to discover and develop novel oral drug candidates. The company's lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19.

Interactive Chart

×